Oxford’s vaccine not recommended for many adults due to insufficient data: report
Top health officials in the EU have cautioned the use of Oxford’s vaccine for COVID-19 among many vulnerable adults: people aged 65 and older.
The British institution’s newly-developed vaccine for SARS-CoV-2 has a purported efficacy rate near 70 percent, placing it behind other vaccines, such as Russia’s Sputnik V, Pfizer-BioNTech’s Comirnaty, and Moderna’s mRNA-1273, all of which have a purported efficacy rate above 90% in comparison.
Oxford and the pharmaceutical company involved in the development of AZD1222 or ‘Vaxzevria’ have induced medical misinformation in the mass media since its origination in a press release, at the start of the pandemic.
French health officials proclaimed that insufficient data on the elderly yielded their recommendation for people aged 65 and over to refrain from receiving the Oxford vaccine, according to a report.
“Currently available data for people aged 65 and over are limited by a small sample size and don’t allow for a conclusion on the safety and the efficacy of the vaccine for this population,” said a top French health official in a news release of the Oxford data.
The report arose as confirmed cases of SARS-CoV-2 surged in the United Kingdom, where new variants have been discovered.
Recent reports also demonstrated the potential for dangerous risks associated with its use in the form of blood clots, with Oxford’s Adrian Hill the culprit behind the deaths caused by the vaccine’s unfortunate effects.
Oxford’s vaccine is set to continue to roll out to the general population in the UK in the coming weeks.